The Influence of Postoperative Lymph Node Radiation Therapy on Overall Survival of Patients With Stage III Melanoma: A National Cancer Data Base Analysis

2016 ◽  
Vol 96 (2) ◽  
pp. S157-S158
Author(s):  
H. Danish ◽  
K. Patel ◽  
J. Switchenko ◽  
T.W. Gillespie ◽  
J. Jhaveri ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Lymph Node ◽  
Data Base ◽  
National Cancer Data Base ◽  
Stage Iii ◽  
Cancer Data ◽  
Base Analysis ◽  
Stage Iii Melanoma

scholarly journals Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis

Cancer ◽  
2017 ◽  
Vol 123 (17) ◽  
pp. 3402-3409 ◽  
Author(s):  
Priscilla K. Stumpf ◽  
Arya Amini ◽  
Bernard L. Jones ◽  
Matthew Koshy ◽  
David J. Sher ◽  
...  
Keyword(s):  
Overall Survival ◽  
Data Base ◽  
Gastric Adenocarcinoma ◽  
Adjuvant Radiotherapy ◽  
National Cancer Data Base ◽  
Cancer Data ◽  
Base Analysis

The National Cancer Data Base report on the utilization of an adjuvant immunotherapy in stage III melanoma in relation to age.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19000-e19000
Author(s):  
Arden Fredeking ◽  
Suraj S. Venna ◽  
Sekwon Jang
Keyword(s):  
Data Base ◽  
Age Groups ◽  
National Cancer Data Base ◽  
Older Age ◽  
Stage Iii ◽  
Care Plan ◽  
High Dose ◽  
Adjuvant Immunotherapy ◽  
Cancer Data ◽  
Stage Iii Melanoma

e19000 Background: The 5-year survival of Stage III melanoma ranges from 30-70%. High dose interferon alfa-2b (IFN) is an adjuvant immunotherapy approved in 1995 for stage III melanoma, however, its use has been limited by its significant toxicity and modest benefit. We hypothesized the utilization of adjuvant immunotherapy is less in older age group compared to younger patients. Methods: Using the National Cancer Data Base (NCDB) aggregate data, demographic, socioeconomic, insurance information, and treatment data were analyzed. Proportions were compared using Pearson Chi squared tests. Results: From 2000-2008, 27,365 cases of stage III melanoma were reported to NCDB. Most patients were male (63%) and Caucasian (94.2%). Twenty-nine percent were over the age of 70. Educational and socioeconomic factors across all age groups were not significantly different. The primary insurer for patients younger than 60 was a managed care plan (54.3%) as compared to Medicare with supplemental insurance for patients older than 60 (47.4%). In terms of systemic therapy, 23% received immunotherapy alone, 6% received chemotherapy alone, 2% received both, and 66% received no therapy. When compared to patients under age 39, older age groups were significantly less likely to receive adjuvant immunotherapy as shown in the table below. Conclusions: There is an inverse relationship between age and the use of adjuvant immunotherapy. Further study is planned to adjust for comorbidity, socioeconomic status using patient-level data. [Table: see text]

Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4519-4519 ◽  
Author(s):  
Claudio Jeldres ◽  
Khanh Ngoc Pham ◽  
Siamak Daneshmand ◽  
Christian K. Kollmannsberger ◽  
Brandon M. Hayes-Lattin ◽  
...  
Keyword(s):  
Overall Survival ◽  
Testicular Cancer ◽  
Data Base ◽  
Clinical Stage ◽  
National Cancer Data Base ◽  
Stage Iii ◽  
Cancer Data ◽  
Institutional Volume
Sign in / Sign up

Export Citation Format

Share Document